Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887792 · ClinicalTrials.gov registry record · Phase 1
Acetazolamide for Treatment Resistant Schizophrenia
A Phase 1 study of Schizophrenia and Schizo Affective Disorder, sponsored by Vishwajit Nimgaonkar, MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04887792 is a Phase 1 study of Schizophrenia and Schizo Affective Disorder that is actively recruiting participants, run by Vishwajit Nimgaonkar, MD PhD. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04887792, a Phase 1 study of Schizophrenia and Schizo Affective Disorder, is actively recruiting participants, sponsored by Vishwajit Nimgaonkar, MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetazolamide
Study Locations (2)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Other
- St John's Medical College Hospital - Bangalore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887792
The ClinicalTrials.gov registry entry for NCT04887792 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The listed sponsor is Vishwajit Nimgaonkar, MD PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04887792 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT04887792 about?
NCT04887792 is a clinical study titled "Acetazolamide for Treatment Resistant Schizophrenia". This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
What is the current status of trial NCT04887792?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-02-01. Estimated completion is 2026-12-30.
What conditions does trial NCT04887792 study?
This clinical trial studies the following conditions: Schizophrenia, Schizo Affective Disorder.
What interventions are being tested in trial NCT04887792?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT04887792?
This trial is sponsored by Vishwajit Nimgaonkar, MD PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04887792 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.